BMEA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biomea Fusion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.73 |
| 52 Week High | US$20.21 |
| 52 Week Low | US$3.61 |
| Beta | -0.37 |
| 1 Month Change | -38.85% |
| 3 Month Change | -64.24% |
| 1 Year Change | -74.64% |
| 3 Year Change | -51.99% |
| 5 Year Change | n/a |
| Change since IPO | -79.95% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Sep 30
We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jun 10We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth
Feb 22Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Nov 07We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jul 12Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Mar 29We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely
Nov 03Biomea Fusion GAAP EPS of -$0.59 beats by $0.01
Aug 01We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Jul 20Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans
Mar 16Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Nov 27Biomea Fusion: Patience Warranted
Sep 23Shareholder Returns
| BMEA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.8% | 0.2% | -0.2% |
| 1Y | -74.6% | -4.7% | 25.8% |
Return vs Industry: BMEA underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: BMEA underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| BMEA volatility | |
|---|---|
| BMEA Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BMEA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BMEA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 107 | Thomas Butler | biomeafusion.com |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc. Fundamentals Summary
| BMEA fundamental statistics | |
|---|---|
| Market cap | US$135.17m |
| Earnings (TTM) | -US$144.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs BMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMEA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$144.01m |
| Earnings | -US$144.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BMEA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 04:17 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biomea Fusion, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Naureen Quibria | Capital One Securities, Inc. |
| Yigal Nochomovitz | Citigroup Inc |